Aetna Wun Trombley - 22 Oct 2026 Form 3 Insider Report for Lycia Therapeutics, Inc.

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
3
Accepted by SEC
22 Oct 2026, 19:10:00 UTC
Prior SEC filing
26 Oct 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Amy Bachrodt, Attorney-in-Fact
Filing notes and source

Key filing fact

Aetna Wun Trombley filed Form 3 for Lycia Therapeutics, Inc. on 22 Oct 2026.

Key facts

  • This page summarizes Aetna Wun Trombley's Form 3 filing for Lycia Therapeutics, Inc..
  • 0 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 22 Oct 2026, 19:10.

Change

  • Previous filing in this sequence was filed on 26 Oct 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001750495 Primary reporting owner

Trombley Aetna Wun

Relationship
President and CEO, Director, 10%+ Owner
Address
C/O LYCIA THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 200, SOUTH SAN FRANCISCO
Signature
/s/ Amy Bachrodt, Attorney-in-Fact
Signature date
22 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
415,255
Date
22 Oct 2026
Ownership
By Trust
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
22 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
471,252
Exercise price
$1.63
Footnotes
F2
No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
22 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
665,380
Exercise price
$2.44
Footnotes
F3
No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
22 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
55,448
Exercise price
$2.35
Footnotes
F4
No ticker holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
22 Oct 2026
Ownership
Direct
Underlying class
Common Stock
Underlying amount
443,586
Exercise price
$3.70
Footnotes
F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These securities are held by the Trombley Family Trust of which the Reporting Person and her spouse are trustees.

Footnote F2

The options are fully vested.

Footnote F3

The options vested as to 1/48 of the total award on July 27, 2024, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F4

The options vested as to 1/48 of the total award on February 1, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Footnote F5

The options vested as to 1/48 of the total award on September 6, 2026, and an additional 1/48 of the award will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .